Drugs / CELZ-201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05626712 | Apr 2023 → Jan 2027 expected | type 1 diabetes mellitus | Creative Medical Technology Holdings Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CELZ-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05626712 ↗ |
| Modality | Cell therapy | “Perinatal tissue derived cells will be administered” NCT05626712 ↗ |
| Route | Other | “via an intra-arterial infusion into the dorsal pancreatic artery.” NCT05626712 ↗ |